![]() |
市場調查報告書
商品編碼
1470553
避孕藥市場:按產品、性別、方法和分佈分類 - 2024-2030 年全球預測Contraceptive Market by Product (Devices, Drugs), Gender (Female Contraceptive, Male Contraceptive), Method, Distribution - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年避孕藥具市場規模為484.3億美元,預計2024年將達548.7億美元,2030年將達1198.9億美元,複合年成長率為13.82%。
避孕藥,也稱為避孕藥具,是用於預防懷孕的方法或裝置。這些產品和設備有多種作用,包括抑制卵子受精、防止受精卵植入子宮、調節荷爾蒙週期。避孕藥具的可用性和選擇使個人能夠計劃何時以及是否想要孩子,從而有助於改善婦女和家庭的健康狀況。為提高性健康和避孕意識而進行的教育宣傳活動和政府措施的增加導致人們更多地採用各種避孕方法。此外,新興國家改善了獲得衛生服務和計劃生育的機會,並增加了避孕藥具的使用。避孕方法的創新帶來了更有效和方便用戶使用的選擇,也推動了市場的成長。然而,嚴格的法律規範可能會延遲產品的核准和推出。在一些地區,由於傳統信仰和宗教限制而產生的阻力也會為市場帶來挑戰。然而,為了迎合具有環保意識的消費者,生物分解性和環保避孕產品的研究預計將成為市場成長的機會。此外,男性避孕用品新興市場的開拓可能很快就會促進市場成長。
主要市場統計 | |
---|---|
基準年[2023] | 484.3億美元 |
預測年份 [2024] | 548.7億美元 |
預測年份 [2030] | 1198.9億美元 |
複合年成長率(%) | 13.82% |
產品:易於使用和非侵入性導致避孕藥物的更高趨勢
保險套被廣泛用作避孕屏障方法,既能避孕又能性行為感染(STI)。保險套通常由乳膠、聚氨酯或小羊皮製成,設計為一次性使用然後丟棄。隔膜是由矽膠或乳膠製成的淺圓頂形杯子,插入陰道腔以覆蓋子宮頸並防止精子到達卵子。隔膜有多種尺寸,必須由醫療保健提供者安裝,以確保正確使用和最大程度的保護。子宮內避孕器 (IUD),例如銅子宮內避孕器,會向子宮中釋放少量銅,為精子創造一個有毒的環境。荷爾蒙子宮內避孕器會釋放一種稱為孕激素的激素,這種激素會使子宮頸黏液變稠並阻止精子到達卵子,這也會抑制排卵。皮下植入是一種插入上臂下方的小桿狀裝置,永續釋放阻止排卵的黃體素。避孕環,例如 NuvaRing,是一種插入陰道的軟性塑膠環,可釋放雌激素和黃體素,以防止懷孕一個月。注射避孕藥是每日避孕藥的替代品,由醫療保健專業人員每三個月注射一次黃體素。口服避孕藥 (OCP) 是最常見的避孕方法,有多種配方,可提供最佳的雌激素和黃體素效果。經皮吸收貼片是放置在皮膚上的荷爾蒙製劑,可將黃體素和雌激素釋放到血液中,以有效控制節育。
性別:由於產品種類繁多,女性避孕藥較受歡迎。
女性避孕藥由多種旨在防止女性意外懷孕的產品組成。這些方法包括荷爾蒙避孕藥,例如口服藥丸、注射和貼片,以及荷爾蒙和銅基子宮內避孕器 (IUD)。包括隔膜、子宮頸帽和女性用保險套在內的避孕方法,以及緊急避孕藥和輸卵管結紮等永久性解決方案,也有助於提供可用的選擇。最常見的男性避孕藥具是保險套和輸精管結紮(永久性外科手術)。然而,男性避孕領域取得了有希望的發展,包括旨在暫時抑制精子產生的荷爾蒙凝膠和注射。此外,研究正在擴展到非荷爾蒙方法,例如可逆精子引導抑制 (RISUG),它在輸精管內充當物理屏障,以及在美國稱為 Vasalgel 的類似方法。男性避孕藥具的接受度和普及度受到文化態度、計劃生育責任感和使用便利性的影響。
方式:越來越偏好在性行為過程中提供物理和化學屏障的屏障避孕方法
屏障避孕的原理是阻止精子到達卵子。這些包括男用和女性用保險套、隔膜、子宮頸帽和避孕海綿,它們描述了性行為過程中的物理或化學屏障。男用保險套是最廣泛使用的屏障方法,因為它們容易取得且易於使用。它不僅可以有效預防懷孕,還可以降低各種性行為感染(STI)的風險。屏障方法通常是首選,因為它們不會對使用者的荷爾蒙產生系統性影響。它含有模仿雌激素和黃體酮天然激素的合成激素,可透過阻止排卵、增厚子宮頸黏液和改變子宮內膜來預防懷孕。有許多不同的類型,包括口服藥、貼片、注射、避孕環和子宮內避孕器 (IUD)。荷爾蒙方法的有效性取決於嚴格遵守使用說明。其他好處包括規律的月經週期、減少月經疼痛以及降低某些生殖癌症的風險。無菌管是透過醫療程序實現的永久性避孕方法,例如女性輸卵管結紮和男性輸精管結紮或輸精管閉塞。這種手術非常有效,失敗率非常低,非常適合那些確定自己將來不想生孩子的人。女性節育手術通常比男性節育手術更複雜,風險也更大。在大多數情況下,這兩種手術都是不可逆的,應該告知考慮節育手術的人,這種節育方法是永久性的。手術避孕是指最終導致不孕的手術,儘管該術語可能與上述不孕方法重疊,但它強調手術因素。對於女性來說,這包括傳統的輸卵管結紮術和最近的手術,例如腹腔鏡在輸卵管中放置閉合裝置。對於男性來說,輸精管切除術涉及切割和封閉切除術。這些永久性手術需要仔細考慮和知情同意。
分銷:透過 24/7 線上藥局加強產品分銷
電子商務的興起擴大了透過線上平台獲得避孕藥具的機會。這些數位市場使消費者能夠輕鬆地大量購買避孕藥具,從而獲得當地可能無法獲得的各種產品。診所是避孕藥具的主要分銷管道,尤其是需要處方箋或諮詢的產品,例如避孕藥、子宮內避孕器和注射。這些醫療保健機構提供了從醫療保健專業人員那裡獲得有關最適合您個人需求的避孕方法的個人化建議和指導的機會。診所可能隸屬於大型醫療機構,也可能獨立營運,通常專注於性健康和生殖健康。診所經常與公共衛生部門合作,為貧困人群提供負擔得起或免費的避孕藥。同時,包括初級衛生中心、社區健康中心、州愛滋病控制協會等在內的政府網路正在針對低收入者和避孕手段有限的地區,往往以低成本或免費分發藥物。這些網路在公共衛生工作中發揮重要作用,有助於讓更多人更容易取得避孕藥具。此外,能夠隨時取得產後和流產後避孕藥具的醫院藥房對於避孕藥具分銷網路至關重要。設有專門生殖健康或計劃生育科室的醫院可能更需要此類產品。醫院藥房是患者的重要網路基地台,他們接受醫療保健專業人員的直接建議並在住院期間尋求保密。此外,獨立藥局和連鎖藥局提供有價值的服務,解決避孕藥具取得的不同方面。獨立藥局專注於個人化照護和社區整合,而連鎖藥局提供有競爭力的價格和便利性。獨立藥局根據當地社區消費者的需求和偏好提供特殊化合物和各種選擇。然而,連鎖藥局的產品陣容通常是按商店標準化的,這可能會限制尋求特定品牌或配方的消費者的選擇。此外,避孕藥等避孕藥具的訂閱服務正變得越來越受歡迎,並且可以透過自動化補充過程來提高用藥依從性。
區域洞察
美洲的避孕藥具市場是一個眾所周知的成熟市場,大型製藥公司的影響力很大。該地區的獨特之處在於其廣泛的避孕方法,包括避孕藥、子宮內避孕器、植入和保險套。美國和加拿大的政府政策和非營利組織在提供可用的避孕方法方面發揮重要作用,特別是對於年輕人和低收入者。在旨在減少少女懷孕和增加避孕藥具供應的公共衛生措施的推動下,拉丁美洲市場正在經歷成長。歐洲、中東和非洲的避孕情況好壞參半。歐洲是一個成熟的市場,避孕普及很高,政府衛生系統可以低成本或免費提供各種避孕方法。人們強烈偏好長效可逆避孕方法 (LARC),例如子宮內避孕器 (IUD)。相較之下,文化和宗教因素影響中東地區避孕藥具的使用,各國的避孕藥具供應情況和社會接受度各不相同。非洲大陸是避孕普及最低的地區之一,國際援助和政府對婦女健康問題的日益關注正在增加對計劃生育服務的需求。亞太地區呈現出多元化的避孕藥具市場,並受到文化、社會和監管因素的顯著影響。人口眾多的國家的存在以及有關避孕藥具使用的政府舉措和宣傳宣傳活動正在推動該地區的市場成長。
FPNV定位矩陣
FPNV定位矩陣對於評估避孕藥市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標,以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估,供應商被分為四個成功程度不同的像限。最前線 (F)、探路者 (P)、利基 (N) 和重要 (V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對避孕市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻,以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外,該分析還提供了對該細分市場競爭特徵的寶貴見解,包括在研究基準年觀察到的累積、碎片化主導地位和合併特徵等因素。詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略,以獲得市場競爭優勢。
1. 市場滲透率:提供有關主要企業所服務的市場的全面資訊。
2. 市場開拓:我們深入研究利潤豐厚的新興市場,並分析其在成熟細分市場的滲透率。
3. 市場多元化:包括新產品發布、開拓地區、最新發展和投資的詳細資訊。
4. 競爭評估和情報:對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。
5. 產品開發與創新:包括對未來技術、研發活動和突破性產品開發的智力見解。
1. 避孕藥市場規模及預測是多少?
2. 在避孕市場的預測期內,我們應該考慮投資哪些產品和應用?
3. 避孕藥具市場的技術趨勢和法規結構是什麼?
4.避孕藥市場主要供應商的市場佔有率是多少?
5. 進入避孕藥具市場的適當形式和策略手段是什麼?
[192 Pages Report] The Contraceptive Market size was estimated at USD 48.43 billion in 2023 and expected to reach USD 54.87 billion in 2024, at a CAGR 13.82% to reach USD 119.89 billion by 2030.
Contraceptives, also known as birth control, are methods or devices used to prevent pregnancy. These products or practices can work in various ways, such as inhibiting the fertilization of an egg, preventing the implantation of a fertilized egg in the uterus, or regulating hormonal cycles. The availability and choice of contraception provide individuals with the ability to plan if and when they want to have children, contributing to better health outcomes for women and families. Increased educational campaigns and government initiatives to raise awareness about sexual health and contraceptives have increased the adoption of various contraceptive methods. Further, enhanced access to healthcare services and family planning in emerging economies has increased the use of contraceptives. Innovations in contraceptive methods leading to more efficient and user-friendly options also bolstered the market growth. However, strict regulatory frameworks can delay product approvals and launches. Resistance in certain regions due to traditional beliefs and religious constraints may pose challenges for the market. Nevertheless, investigating biodegradable and eco-friendly contraceptive products to cater to environmentally conscious consumers is expected to provide an opportunistic way for market growth. Moreover, developments in male contraception methods may bolster the market growth shortly.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 48.43 billion |
Estimated Year [2024] | USD 54.87 billion |
Forecast Year [2030] | USD 119.89 billion |
CAGR (%) | 13.82% |
Product: High inclination toward contraceptive drugs due to their ease of use and non-invasiveness
Condoms are a widely used barrier method of contraception that provides both birth control and protection against sexually transmitted infections (STIs). Condoms are usually made of latex, polyurethane, or lambskin and are designed to be used once and disposed of after use. The diaphragm is a shallow, dome-shaped cup made of silicone or latex that is inserted into the vaginal cavity to cover the cervix and block sperm from reaching the ovum. Diaphragms are available in various sizes, and a healthcare provider must fit them to ensure proper use and maximum protection. Intrauterine devices (IUDs) such as Copper IUDs release a small amount of copper into the uterus, which creates a toxic environment for sperm. Hormonal IUDs release progestin, a hormone that thickens the cervical mucus to prevent sperm flow from reaching the egg and sometimes suppresses ovulation. Subdermal implants are small, rod-shaped devices inserted below the upper arm, releasing a continuous amount of progestin hormone to prevent ovulation. Vaginal rings, such as the NuvaRing, are flexible plastic rings that are inserted into the vagina and release both estrogen and progestin to offer month-long pregnancy protection. Injectable contraceptives are injections of progestin given by a healthcare professional every three months as an alternative to daily contraceptive pills. Oral contraceptive pills (OCPs) are the most common methods of contraception, available in various formulations of estrogen and progestin for optimal effectiveness. The transdermal patch is a hormonal contraceptive applied to the skin, releasing progestin and estrogen into the bloodstream to effectively control contraception.
Gender: Significant adoption of female contraceptives due to availability of a wide range of products
The female contraceptive comprises a diverse range of products aimed at enabling women to prevent unintended pregnancies. These methods include hormonal contraceptives such as oral contraceptive pills, injectables, and patches, as well as intrauterine devices (IUDs), both hormonal and copper-based. Contraceptive methods, including diaphragms, cervical caps, and female condoms, also contribute to the options available, alongside emergency contraceptive pills and permanent solutions such as tubal ligation. The most common male contraceptives include condoms and vasectomy, a permanent surgical procedure. However, there are promising developments in the field of male contraception, such as hormonal gels and injections that aim to inhibit sperm production temporarily. Furthermore, research into non-hormonal methods, including the reversible inhibition of sperm under guidance (RISUG) and a similar method in the U.S. known as Vasalgel, which acts as a physical barrier inside the vas deferens, is expanding. The acceptance and popularity of male contraceptives are influenced by cultural attitudes, perceived responsibility in family planning, and the convenience of use.
Method: Rising preference for barrier methods of contraception that provide a physical and chemical barrier during sexual activities
Barrier methods of contraception work by preventing the sperm from reaching the egg. These include male and female condoms, diaphragms, cervical caps, and contraceptive sponges, providing a physical or chemical barrier during sexual activities. Male condoms are the most widely used barrier method as they are readily available and easy to use. In addition to preventing pregnancy, these are effective in reducing the risk of various sexually transmitted infections (STIs). Barrier methods are often favored for their lack of systemic effects on the user's hormones. Hormonal contraceptives contain synthetic hormones that mimic estrogen and progesterone's natural hormones to prevent ovulation, thicken cervical mucus, or alter the uterine lining to prevent pregnancy. These types come in various forms, including oral pills, patches, injections, vaginal rings, and intrauterine devices (IUDs). The effectiveness of hormonal methods depends on strict adherence to their usage regimen. Additionally, these methods can offer benefits such as regulated menstrual cycles, reduced menstrual cramps, and a decreased risk of certain reproductive cancers. Sterilization is a permanent form of birth control achieved through medical procedures that close or block the fallopian tubes in females (tubal ligation) or the vas deferens in males (vasectomy). The procedures are highly effective with a very low rate of failure and are best suited for individuals who are sure they do not want children in the future. Female sterilization is usually more complex and carries greater risks than male sterilization, which is often a simpler outpatient procedure. Both procedures are irreversible in most cases, and individuals considering sterilization should be counseled on the permanent nature of this contraceptive method. Surgical contraception refers to procedures that ultimately lead to sterilization, and while the term may overlap with sterilization methods mentioned, it emphasizes the factor of surgery. For women, this includes both traditional tubal ligation and more recent procedures, such as the laparoscopic placement of occlusive devices on the fallopian tubes. For men, vasectomy involves the cutting and sealing of the vas deferens. These permanent procedures require careful consideration and informed consent, as reversal attempts may not be successful and are often costly.
Distribution Channel: Enhanced product distribution through online pharmacies due to their 24/7 services
The rise of eCommerce has expanded the availability of contraceptives through online platforms. These digital marketplaces allow consumers to purchase contraceptives discretely and conveniently, providing access to various products that may not be available in their immediate geographical area. Clinics serve as a primary distribution channel for contraceptives, particularly for forms requiring prescription or medical consultation, such as birth control pills, IUDs, and injectables. These healthcare facilities provide an opportunity for individuals to receive personalized advice and guidance from health professionals about the most appropriate contraceptive method for their needs. Clinics may be affiliated with larger healthcare institutions or operate independently, often focusing on sexual and reproductive health. They often work in conjunction with public health initiatives to provide affordable or free contraceptives to underprivileged populations. On the other hand, Government networks, including Primary Health Centers, Community Health Centers, State AIDS Control Societies, and many others, distribute contraceptives often at reduced or no cost, targeting lower-income brackets and regions with limited access to healthcare. These networks have a crucial role in public health initiatives and are instrumental in making contraceptives accessible to a broader audience. Further, hospital pharmacies are integral to the distribution network for contraceptives as they provide immediate access to postpartum and post-abortion contraceptives. Hospitals with specialized reproductive health or family planning divisions may need such products more. Hospital pharmacies are an important access point for patients seeking confidentiality and direct recommendations from healthcare providers during their hospital stay. Furthermore, independent and chain pharmacies offer valuable services catering to different aspects of contraceptive access. Independents focus on personalized care and community integration, while chains excel in price competitiveness and convenience. Independent pharmacies offer specialized compounds and a range of options tailored to consumer feedback and preferences in their local community. However, chain pharmacy product range is often standardized across locations, potentially limiting options for consumers seeking specific brands or formulations. Moreover, subscription services for contraceptives, such as birth control pills, have become increasingly popular and can improve adherence by automating the refill process.
Regional Insights
The contraceptive market in the Americas presents a mature landscape with high awareness levels and a strong presence of major pharmaceutical companies. The region is characterized by a wide range of contraceptive methods including birth control pills, IUDs, implants, and condoms. Government policies and non-profit organizations in the United States and Canada play a crucial role in providing accessible contraception, particularly to younger and lower-income populations. The Latin American market is experiencing growth, propelled by public health initiatives aimed at reducing teenage pregnancies and increasing the availability of contraceptives. The EMEA region presents a varying landscape for contraceptives. Europe has a well-established market with high contraceptive prevalence rates, backed by governmental healthcare systems that offer various contraceptive methods at low or no cost. There is a strong tendency toward long-acting reversible contraceptives (LARCs) such as IUDs. The Middle East, contrastingly, has cultural and religious factors that influence contraceptive use, with varying degrees of accessibility and societal acceptance across different countries. The African continent shows the lowest contraceptive prevalence rate and is experiencing a rise in need for family planning services, driven by international aid, and increasing government focus on women's health issues. The Asia-Pacific region showcases a diverse contraceptive market, heavily influenced by cultural, social, and regulatory factors. The presence of high-population countries coupled with government initiatives and awareness campaigns for the use of contraceptives has propelled the market growth in the region.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Contraceptive Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Contraceptive Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Contraceptive Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Acme Generics Pvt. Ltd., Afaxys, Inc., Agile Therapeutics, Inc., Amneal Pharmaceuticals LLC, ASKA Pharmaceutical Co., Ltd., Aurobindo Pharma Limited, Bayer AG, Church & Dwight Co., Inc., HLL Lifecare Limited, Insud Pharma, S.L., Johnson & Johnson Services, Inc., Lupin Limited, Mayne Pharma Group Limited, Merck & Co., Inc., Mithra Pharmaceuticals S.A., Okamoto Industries, Inc., Organon & Co., Perrigo Company plc, Pfizer Inc., Piramal Pharma Ltd., Reckitt Benckiser Group plc, RITEX GMBH, Sanofi S.A., Say It With A Condom, LLC., Syzygy Healthcare Solutions LLC, Teva Pharmaceutical Industries Ltd., TherapeuticsMD, Inc., TTK Healthcare Limited, Veru Inc., and Viatris Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Contraceptive Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Contraceptive Market?
3. What are the technology trends and regulatory frameworks in the Contraceptive Market?
4. What is the market share of the leading vendors in the Contraceptive Market?
5. Which modes and strategic moves are suitable for entering the Contraceptive Market?